Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer

Overview

Journal Front Physiol

Date 2018 Aug 18

PMID 30116199

Citations 6

Authors

Ying-Mei Lin

Jun Shao

Xiao-Hong Yin

Caicai Huang

Xiao-Wei Jia

Ya-Di Yuan

Chang-Jing Wu

En-Ming Zhen

Zhong-Xiong Yao

Xian-Tao Zeng

Rui-Hua Liu

Affiliations

Soon will be listed here.

Abstract

TP53 is an important tumor suppressor gene to maintain genomic integrity, and its mutations increase the susceptibility to oral carcinoma. Previous published studies have reported the relation of TP53 codon 72 polymorphism with the risk of oral carcinoma, but the results remain controversial and inconclusive. We therefore utilized meta-analysis based on a comprehensive search in PubMed, EMBASE, and Google of Scholar databases up to August 19, 2017. Total 3,525 cases and 3,712 controls from 21 case-control studies were selected. We found no significant association between TP53 codon 72 polymorphism and oral carcinoma susceptibility in all genetic contrast models, including subgroup analysis based on control source and ethnicity. Furthermore, TP53 codon 72 polymorphism was not significant associated with oral carcinoma susceptibility in tobacco or alcohol use, and HPV infection status. Our results were confirmed by sensitivity analysis and no publication bias was found. Taken together, our data indicate that TP53 codon 72 polymorphism is not associated with the susceptibility to oral carcinoma.

Citing Articles

p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications.

Benitez D, Cumplido-Laso G, Olivera-Gomez M, Del Valle-Del Pino N, Diaz-Pizarro A, Mulero-Navarro S Biomedicines. 2024; 12(7).

PMID: 39062026 PMC: 11274425. DOI: 10.3390/biomedicines12071453.

Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders.

Li H, Liu Y, Zhou S, Zhou Q, Yang X BMC Oral Health. 2023; 23(1):659.

PMID: 37697274 PMC: 10496165. DOI: 10.1186/s12903-023-03316-0.

TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study.

Datkhile K, Bhosale S, Durgawale P, Jagdale N, More A, Gudur R Asian Pac J Cancer Prev. 2023; 24(5):1611-1619.

PMID: 37247280 PMC: 10495895. DOI: 10.31557/APJCP.2023.24.5.1611.

Feline Oral Squamous Cell Carcinoma: A Critical Review of Etiologic Factors.

Sequeira I, Pires M, Leitao J, Henriques J, Viegas C, Requicha J Vet Sci. 2022; 9(10).

PMID: 36288171 PMC: 9609408. DOI: 10.3390/vetsci9100558.

Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Gonzalez-Moles M, Warnakulasuriya S, Lopez-Ansio M, Ramos-Garcia P Cancers (Basel). 2022; 14(15).

PMID: 35954497 PMC: 9367256. DOI: 10.3390/cancers14153834.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Slee E, OConnor D, Lu X . To die or not to die: how does p53 decide?. Oncogene. 2004; 23(16):2809-18. DOI: 10.1038/sj.onc.1207516. View

Baker S, Preisinger A, Jessup J, Paraskeva C, Markowitz S, WILLSON J . p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50(23):7717-22. View

Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A . The role of TP53 in Cervical carcinogenesis. Hum Mutat. 2003; 21(3):307-12. DOI: 10.1002/humu.10178. View

Chor J, Vlantis A, Chow T, Fung S, Ng F, Lau C . The role of human papillomavirus in head and neck squamous cell carcinoma: A case control study on a southern Chinese population. J Med Virol. 2015; 88(5):877-87. DOI: 10.1002/jmv.24405. View

Jing G, Lv K, Jiao X . The p53 codon 72 polymorphism and the risk of oral cancer in a Chinese Han population. Genet Test Mol Biomarkers. 2012; 16(9):1149-52. DOI: 10.1089/gtmb.2012.0138. View

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

Ye Y, Lippman S, Lee J, Chen M, Frazier M, Spitz M . Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008; 113(9):2488-95. PMC: 2577230. DOI: 10.1002/cncr.23854. View

Zarate A, Don J, Secchi D, Carrica A, Galindez Costa F, Panico R . Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients. Tumour Biol. 2017; 39(5):1010428317699113. DOI: 10.1177/1010428317699113. View

10.

Coleman M, Quaresma M, Berrino F, Lutz J, De Angelis R, Capocaccia R . Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9(8):730-56. DOI: 10.1016/S1470-2045(08)70179-7. View

11.

Whibley C, Pharoah P, Hollstein M . p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009; 9(2):95-107. DOI: 10.1038/nrc2584. View

12.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

13.

Lin Y, Huang H, Wang L, Tsai C, Lung O, Dai C . Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008; 44(8):798-804. DOI: 10.1016/j.oraloncology.2007.10.006. View

14.

Wang Z, Sturgis E, Zhang Y, Huang Z, Zhou Q, Wei Q . Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 2011; 131(3):E251-8. PMC: 3289741. DOI: 10.1002/ijc.27335. View

15.

Drummond S, De Marco L, Pordeus I, Barbosa A, Gomez R . TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 2003; 22(6A):3379-81. View

16.

Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A . Association of P53 codon 72 polymorphism and ameloblastoma. Oral Dis. 2010; 16(7):631-5. DOI: 10.1111/j.1601-0825.2010.01664.x. View

17.

Zhuo X, Cai L, Xiang Z, Zhuo W, Wang Y, Zhang X . TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res. 2009; 40(4):299-305. DOI: 10.1016/j.arcmed.2009.03.006. View

18.

Ji X, Neumann A, Sturgis E, Adler-Storthz K, Dahlstrom K, Schiller J . p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 2008; 29(4):875-9. DOI: 10.1093/carcin/bgn039. View

19.

Harris S, Levine A . The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24(17):2899-908. DOI: 10.1038/sj.onc.1208615. View

20.

Shield K, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi A, Bray F . The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017; 67(1):51-64. DOI: 10.3322/caac.21384. View